Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis

doi:10.3748/wjg.v18.i43.6290

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 18, Issue 43

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (3990)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-2) series.

Item

Count

PDF

360

HTML

3164

Figures (1-3)

237

Tables (1-2)

229

Sum=3990

Nov 21, 2012 (publication date) through Dec 24, 2024

Times Cited of This Article

Times Cited (10)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Gastroenterol. Nov 21, 2012; 18(43): 6290-6301
Published online Nov 21, 2012. doi: 10.3748/wjg.v18.i43.6290

Full Size Figure Download Figure

Figure 2 Meta-analysis of the two groups. A: Hepatitis B virus DNA undetectability; B: Alanine aminotransferase normalization; C: Hepatitis B e antigen (HBeAg) loss; D: HBeAg seroconversion; E: Drug-resistance; F: Increased creatine kinase (CK). ETV: Entacavir; LDT: Telbivudine.

Citation: Su QM, Ye XG. Effects of telbivudine and entecavir for HBeAg-positive chronic hepatitis B: A meta-analysis. World J Gastroenterol 2012; 18(43): 6290-6301
URL: https://www.wjgnet.com/1007-9327/full/v18/i43/6290.htm
DOI: https://dx.doi.org/10.3748/wjg.v18.i43.6290